Adc Therapeutics Sa

Health Care
Biotechnology: Pharmaceutical Preparations
www.adctherapeutics.com

Safety Score

Market Cap $247.95M
Debt $113.82M
Cash $194.70M
EV $167.07M
FCF -$136.67M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$149.84M
EBIT	-$98.87M
ROA	-36%
FCF	-$136.67M
Equity	-$238.22M
Growth Stability	1
PE	-1.65
PB	-1.04
P/FCF	-1.81
P/S	3.27
Price/Cash	0.79
Debt/Equity	-0.48
Debt/FCF	-0.83
Net Margins	-168%
Op. Margins	-130%
Sales Growth YoY	28%
Sales Growth QoQ	36%
Sales CAGR	0%
Earnings Growth YoY	-17%

Earnings Growth QoQ	26%
Sales CAGR 5Y	0%
Earnings CAGR 3Y	2%
Sales CAGR 3Y	2%
Market Cap	$247.95M
Revenue	$75.82M
Assets	$272.54M
Total Debt	$113.82M
Cash	$194.70M
Shares Outstanding	99.18M
EV	167.07M
Safety Score	34%
Working Capital	200.2M
Current Ratio	4.46
Shares Growth 3y	11%
Equity Growth QoQ	18%
Equity Growth YoY	23%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

SEC Filings

Direct access to Adc Therapeutics Sa (ADCT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31

Sector Comparison

How does Adc Therapeutics Sa compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Adc Therapeutics Sa compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Adc Therapeutics Sa Discounted Cash Flow

Fully customizable DCF calculator online for Adc Therapeutics Sa.

Years

Calculation mode

= -$1.4B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$137M	-$137M	-$137M	-$137M	-$137M	-$137M	-$137M	-$137M	-$137M	-$137M	-$137M	-$1.4B
DCF		-$124M	-$113M	-$103M	-$93M	-$85M	-$77M	-$70M	-$64M	-$58M	-$53M	-$527M
Value	-$1.4B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-	-	-	-	-75%	-345%	-223%	-168%
ROA	-	-	-	-	-	-42%	-33%	-36%
ROE	-	-	-	-149%	-198%	162%	78%	-

Bad Net Margins (-167.59%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-	-	-0.92	-0.91	-0.83
Debt over Equity	-	-	-	-	1.38	-0.76	-0.56	-0.48
Growth Stability	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-0.83)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (-0.48)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-67%	2%	0%
Earnings YoY growth	-	-5%	111%	-7%	-32%	53%	-34%	-
Equity YoY growth	-	-	-	-	-48%	-287%	37%	-
FCF YoY growth	-	-	-	-	-	-12%	2%	-